TOKYO, May 14 (Pulse News Wire) – J-pharma CO.,LTD. (520A.T) reported non-operational revenue of ¥605.4 million from a government grant received during its fiscal fourth quarter ending March 31, 2026.
The grant was awarded by the National Center for Biotechnology Information (NCBI) through its "Drug Venture Eco-system Strengthening Program," supporting research and development of a novel LAT1 inhibitor for multiple sclerosis until March 24, 2026. Additionally, the company had previously recorded ¥414.6 million in grants during the third quarter of the same fiscal year, bringing the total grant income for the fiscal year 2026 to ¥1.020 billion.
The impact of this non-operational revenue on the overall performance will be detailed in the full consolidated earnings release published today. For further insights into the financial implications, investors should refer to the interim unaudited financial statements released concurrently.
🟢 Confidence: High AI-translated content.